Who are BNT323/DB-1303's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elrexfio, Elrexfio, Elrantamab, BAT2206, MRG003 + Pucotenlimab, JSKN003.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bnt323-db-1303.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BNT323/DB-1303 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BNT323/DB-1303 (BNT323/DB-1303) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody. Area: Oncology.

phase 3 Bispecific antibody Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BNT323/DB-1303 (BNT323/DB-1303) — BioNTech SE. BNT323/DB-1303 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to redirect immune responses against cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BNT323/DB-1303 TARGET	BNT323/DB-1303	BioNTech SE	phase 3	Bispecific antibody
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrantamab	elrantamab	Pfizer	marketed	Bispecific Antibody	BCMA (B-cell maturation antigen)
BAT2206	BAT2206	Bio-Thera Solutions	phase 3	Bispecific antibody; dual checkpoint inhibitor	Likely PD-1 and LAG-3 (or similar dual checkpoint targets)
MRG003 + Pucotenlimab	MRG003 + Pucotenlimab	Shanghai Miracogen Inc.	phase 3	Bispecific antibody (MRG003) + PD-L1 inhibitor (Pucotenlimab)	PD-L1, 4-1BB (MRG003); PD-L1 (Pucotenlimab)
JSKN003	JSKN003	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	phase 3	Bispecific antibody; immune checkpoint inhibitor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BNT323/DB-1303 — Competitive Intelligence Brief. https://druglandscape.com/ci/bnt323-db-1303. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing